Large Platform Agreement Targeting Multiple Products

Novartis AG (NVS) has entered into an option and license agreement with Alteogen Inc. (KOSDAQ:196170) for ALT-B4. Through multiple option exercises, Novartis will secure exclusive rights to develop and commercialize subcutaneous (SC) formulations of multiple biopharmaceuticals. If all options and development and commercialization milestones are achieved, Alteogen's total receipts will exceed $3.2 billion, with additional royalties based on net sales after commercialization. While the specific drug applications are not listed in the announcement, the asset-specific option structure reflects Novartis' portfolio strategy to control early risks and concentrate capital on successful programs.

How ALT-B4 Works and Its Development Stage

ALT-B4 is a recombinant human hyaluronidase developed using the Hybrozyme platform, with the generic name berahyaluronidase alfa. It temporarily degrades hyaluronic acid in the extracellular matrix of subcutaneous tissue, enabling broad dispersion and absorption of high-dose antibodies, thereby converting intravenous (IV) biopharmaceuticals into SC formulations. The platform itself is already in commercialization with Merck & Co. (MRK)'s Keytruda Qlex. Keytruda Qlex is a combination of the PD-1-targeting antibody pembrolizumab and berahyaluronidase alfa-pmph, which was approved by the FDA on September 19, 2025.

Competitive Landscape Proven by Approved Products

The key competitor in the same market is Halozyme Therapeutics (HALO)'s ENHANZE recombinant PH20 platform. ENHANZE-based standard competitive products include Roche (RHHBY)'s Tecentriq Hybreza, a combination of the PD-L1-targeting atezolizumab and hyaluronidase-tqjs, which received FDA approval on September 12, 2024. Bristol Myers Squibb (BMY)'s Opdivo Qvantig, a combination of the PD-1-targeting nivolumab and hyaluronidase-nvhy, was also approved by the FDA in December 2024, without an advisory committee meeting. Therefore, Alteogen is competing with Halozyme using a commercialized, validated technology rather than a preclinical platform.

Market Potential and Pipeline Scalability

The global subcutaneous biopharmaceutical market is projected to grow from $25.755 billion in 2025 to $28.63 billion in 2026 and $49.89 billion in 2031, with a compound annual growth rate (CAGR) of 11.75% from 2026 to 2031. The shift from IV to SC administration not only improves patient convenience but also affects infusion center capacity, administration costs, and brand defense after biosimilar entry. Alteogen has signed agreements with GSK's Jemperli SC and up to two assets from Biogen, each including an upfront payment of $20 million, and has expanded its customer diversification through this Novartis deal. However, most of the $3.2 billion is tied to option exercises and subsequent performance, so the number of applied assets and the speed of clinical entry will be key to value realization rather than short-term cash inflow.